Stockscreener 앱 받기
0.93
1.06%
-0.010
전일 마감가:
$0.94
열려 있는:
$0.93
하루 거래량:
90,557
Relative Volume:
0.76
시가총액:
$68.25M
수익:
$33.79M
순이익/손실:
$-18.67M
주가수익비율:
-2.5963
EPS:
-0.3582
순현금흐름:
$-19.17M
1주 성능:
-14.68%
1개월 성능:
-4.12%
6개월 성능:
+7.86%
1년 성능:
+5.68%
1일 변동 폭
$0.8999
$0.93
1주일 범위
$0.87
$1.12
52주 변동 폭
$0.70
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
명칭
Cytosorbents Corp
전화
973-329-8885
주소
305 COLLEGE ROAD EAST, PRINCETON, NJ
CTSO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
0.93 | 68.25M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
132.22 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.45 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
381.83 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.39 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.38 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-07 | 개시 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2020-09-17 | 개시 | Jefferies | Buy |
| 2020-09-01 | 개시 | SVB Leerink | Outperform |
| 2017-08-08 | 재확인 | Maxim Group | Buy |
| 2016-10-26 | 개시 | Aegis Capital | Buy |
| 2016-05-24 | 개시 | Maxim Group | Buy |
| 2015-10-29 | 업그레이드 | WBB Securities | Speculative Buy → Buy |
| 2015-05-12 | 재확인 | MLV & Co | Buy |
| 2015-04-01 | 재확인 | MLV & Co | Buy |
| 2015-03-05 | 개시 | MLV & Co | Buy |
| 2015-02-25 | 개시 | WBB Securities | Speculative Buy |
| 2015-01-27 | 재확인 | H.C. Wainwright | Buy |
모두보기
Cytosorbents Corp 주식(CTSO)의 최신 뉴스
Cytosorbents’ (CTSO) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Behind Cytosorbents Corp’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Today’s watch list includes Cytosorbents Corp (NASDAQ:CTSO) stock - uspostnews.com
CytoSorbents (CTSO) Stock: Analyst Maintains "Buy" Rating with $ - GuruFocus
Demystifying CytoSorbents: Insights From 4 Analyst Reviews - Benzinga
FDA denies CytoSorbents’ request for DrugSorb-ATR device - Investing.com
CytoSorbents: FDA issues denial letter for De Novo Request for DrugSorb-ATR - TipRanks
CytoSorbents (CTSO) Awaits FDA Approval for Breakthrough Device DrugSorb-ATR | CTSO Stock News - GuruFocus
CytoSorbents Provides Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents (NASDAQ:CTSO) versus Microbot Medical (NASDAQ:MBOT) Financial Analysis - Defense World
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights - Longview News-Journal
CytoSorbents, Blood Purification Leader, Reveals Q1 2025 Results and Business Updates May 14 - Stock Titan
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents secures $1.7M via NJ tax credit transfer - Investing.com
CytoSorbents Lands $1.7M Strategic Funding: New DrugSorb Product Launch and Manufacturing Expansion Ahead - Stock Titan
Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com - Defense World
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller - PR Newswire
Cytosorbents Appoints Thomas Shannon As Vice President Of Marketing For North America - marketscreener.com
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America - PR Newswire
Strategic Hire: Medtronic $450M Portfolio Leader Joins CytoSorbents to Drive Breakthrough Device Launch - Stock Titan
Raymond James Financial Inc. Takes Position in Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Now Covered by Analysts at StockNews.com - Defense World
Analysts Offer Predictions for Cytosorbents Q1 Earnings - Defense World
Brokers Offer Predictions for Cytosorbents Q1 Earnings - Defense World
Analysts Set Expectations for Cytosorbents FY2028 Earnings - Defense World
Cytosorbents (NASDAQ:CTSO) Earns “Neutral” Rating from HC Wainwright - Defense World
CytoSorbents extends Series B Warrants expiration to June 10 - Investing.com
Cytosorbents CorpExtends Expiration Date Of Series B Right Warrants To June 10, 2025SEC Filing - MarketScreener
CytoSorbents extends Series B Warrants expiration to June 10 By Investing.com - Investing.com UK
CytoSorbents Gives Investors More Time: Series B Warrants Now Extended to June 2025 - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com - Defense World
Cytosorbents (NASDAQ:CTSO) Given Buy Rating at D. Boral Capital - Defense World
Cytosorbents Corp Reports Strong Growth Amid Challenges - TipRanks
CytoSorbents Corp Q4 2024 Earnings: EPS Misses at -$0.06, Revenue Falls Short at $9.2 Million - GuruFocus
The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts - Benzinga
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2024 Earnings Call Transcript - Insider Monkey
CytoSorbents: Q4 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Cytosorbents (CTSO) Sees Significant Growth in Q4 and 2024 Reven - GuruFocus
CytoSorbents Corp (CTSO) Q4 2024 Earnings Call Highlights: Stron - GuruFocus
CytoSorbents Corporation Reports Strong 2024 Performance - TipRanks
Earnings call transcript: Cytosorbents Crp Q4 2024 beats EPS forecast By Investing.com - Investing.com Canada
CTSOCytosorbents Corp Latest Stock News & Market Updates - Stock Titan
Cytosorbents Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Cytosorbents Corp SEC 10-K Report - TradingView
CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - TradingView
CYTOSORBENTS Earnings Results: $CTSO Reports Quarterly Earnings - Nasdaq
Cytosorbents (CTSO) Expected to Post Improved Earnings and Reven - GuruFocus
Insights into CytoSorbents's Upcoming Earnings - Benzinga
CytoSorbents Corp (CTSO) Q4 2024 Earnings Report Preview: What t - GuruFocus.com
Cytosorbents (CTSO) Expected to Announce Quarterly Earnings on Monday - Defense World
Cytosorbents Corp (CTSO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10.11%
0.04%
자본화:
|
볼륨(24시간):